 9. Since the standard of care would have been to remove the CVC, the primary end point of the study will be the number and percent of patients who successfully received antifungal lock therapy, i.e., those patients with at least 2 negative fungal cultures before the completion of 5 days of antifungal lock therapy and whose CVCs were not removed. Secondary endpoints will include the number of days before the cultures become negative; the development of fungal-related complications e.g., septic arthritis, endocarditis, etc.; and the development of recurrent candidemia on day 5 and day 30 post antifungal lock therapy. 